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Abstract
Background The recommended treatment of Pneumo-
cystis jirovecii pneumonia (PCP) is high-dose trimetho-
prim–sulfamethoxazole (TMP–SMX) in an equivalent of
TMP 15–20 mg/kg/day and SMX 75–100 mg/kg/day for 2
or 3 weeks. High rates of adverse events are reported with
this dose, which raises the question if lower doses are
possible.
Methods All adult patients diagnosed with PCP in various
immune dysfunctions and treated with TMP–SMX between
January 1, 2003 and July 1, 2013 in a tertiary university
hospital were included. Per institutional protocol, patients
initiated treatment on intermediate-dose TMP–SMX (TMP
10–15 mg/kg/day) and could be stepped down to low-dose
TMP–SMX (TMP 4–6 mg/kg/day) during treatment.
Clinical variables at presentation, relapse rate and mortality
rates were compared between intermediate- and step-down
treatment groups by uni- and multivariate analyses.
Results A total of 104 patients were included. Twenty-
four patients (23 %) were switched to low-dose TMP–
SMX after a median of 4.5 days (IQR 2.8–7.0 days). One
relapse (4 %) occurred in the step-down group versus none
in the intermediate-dose group. The overall 30-day mor-
tality was 13 %. There was 1 death in the step-down group
(4 %) compared to 13 deaths (16 %) in the intermediate-
dose group.
Conclusions We observed high cure rates of PCP by
treatment with intermediate-dose TMP–SMX. In addition,
a step-down strategy to low-dose TMP–SMX during
treatment in selected patients appears to be safe and does
not compromise the outcome of treatment.
Keywords Pneumocystis jirovecii  Treatment  Low
dose  Cotrimoxazole  Trimethoprim–sulfamethoxazole 
Antibiotic stewardship
Introduction
According to current guidelines and reviews, the recom-
mended treatment of Pneumocystis jirovecii pneumonia
(PCP) is high-dose trimethoprim–sulfamethoxazole (TMP–
SMX) in a dose of TMP 15–20 mg/kg/day and SMX
75–100 mg/kg/day for a duration of 2 or 3 weeks [1–3].
Most, if not all, of the evidence for this regimen is based on
animal studies [4] and a small open label trial comparing
high- versus low-dose TMP–SMX for the treatment of PCP
in immunocompromised children [5]. In this clinical study
performed almost 40 years ago, numerically more patients
recovered on the high-dose regimen of TMP 20 mg/
kg/day–SMX 100 mg/kg/day (11 out of 14) than when
receiving TMP 4–7 mg/kg/day–SMX 20–35 mg/kg/day (3
out of 6). In randomized trials comparing different thera-
peutic options for the treatment of HIV-associated PCP,
high-dose TMP–SMX was always present as one of both
treatment arms [6–10]. Irrespective of the response rates on
high-dose TMP–SMX, high rates of adverse events and
drug toxicity were observed. Rash, drug fever, neutropenia,
renal insufficiency, electrolyte disorders and liver toxicity
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were all encountered frequently. In the above-named trials,
the severity of the side effects forced clinicians to switch to
an alternative treatment (like pentamidine, dapsone–
trimethoprim or clindamycin–primaquine) in over 30 % of
patients that were included in the high-dose TMP–SMX
arms.
Limited retrospective data and one small randomized
trial demonstrated that treatment of PCP with an interme-
diate dose of TMP–SMX (TMP 10 mg/kg/day and SMX
50 mg/kg/day) yielded comparable efficacy as the tradi-
tional high-dose regimen [11, 12]. Moreover, the inter-
mediate dose was associated with lower rate of observed
toxicity and treatment limiting adverse effects. The effi-
cacy of treatment with low-dose TMP–SMX (TMP
4–6 mg/kg/day and SMX 20–30 mg/kg/day) has not been
investigated in a clinical setting ever since the first intro-
duction of TMP–SMX for the treatment of PCP by Hughes
et al. in 1975. However, the safety and comparable efficacy
of a step-down strategy to low-dose TMP–SMX after
observation of adverse events was demonstrated in a small
prospective study in 1990 [13].
Regarding the limited evidence from clinical studies as
well as the high burden of drug toxicity and treatment
limiting adverse events, rationale is provided for movement
away from the generally recommended high-dose TMP–
SMX regimen. Since several years we routinely used in our
institution an intermediate dose of TMP–SMX for all
patients diagnosed with PCP. After starting this interme-
diate-dose regimen, it is an option for the attending clini-
cian to switch to low-dose TMP–SMX based on
observation of good clinical response or drug-related tox-
icity. In this study, we present the outcomes of this alter-
native treatment strategy. In addition, we assessed whether
clinical characteristics at presentation may be indicative for
later switching to low-dose TMP–SMX. In Table 1, an
overview of the different dosing regimens referred to in
this article is provided.
Methods
Setting and study population
The study was performed in the Leiden University Medical
Center, a tertiary care and teaching hospital in the
Netherlands with solid organ and haematological
transplantation programs as well as providing care for HIV-
seropositive patients. The study was approved by the ethics
committee of the Leiden University Medical Center.
Written informed consent was not obtained, since patient
information was anonymized and the methods of the study
did not require informed consent under common law and
ethics.
The databases of the Department of Medical Microbi-
ology and the Pharmacy Department were cross-linked to
identify all adult patients diagnosed with PCP and treated
with TMP–SMX between January 1, 2003 and July 1,
2013. A confirmed diagnosis of PCP was defined as pres-
ence of respiratory symptoms, radiological evidence (in-
terstitial pneumonitis on chest X-ray or computed
tomography) and positive microbiological test, i.e. a posi-
tive polymerase chain reaction (PCR) and/or positive
microscopy for P. jirovecii cysts by silver and Giemsa
staining in bronchoalveolar lavage (BAL) fluid or induced
sputum. Except for the implementation of a real-time-PCR
method for detection of the dihydropteroate synthase
(DHPS) coding region of P. jirovecii DNA in 2004 [14],
the diagnostic and treatment protocols for PCP did not
change during the study period. Confirmed cases were
included in a retrospective cohort study. Patients that
were\18 years old or who were treated with other regi-
mens active against P. jirovecii were excluded from the
analyses. Relapse of PCP was defined as a new diagnosis of
PCP within 30 days after completion of at least a 2-week
course of treatment after which clinical cure was achieved.
In case of relapse, only the first episode of PCP was
included.
Treatment conditions
Initial, protocolled treatment for all patients diagnosed with
PCP consisted of intermediate-dose TMP–SMX adminis-
tered by oral or intravenous route twice daily. In Table 1,
the different dosing regimens are specified. The standard
duration of treatment was 2 weeks. Additional steroid
therapy was started if the partial oxygen pressure
was\9.0 kPa. After commencing treatment with the
intermediate dose, a step-down strategy to low-dose TMP–
SMX could be followed as per decision of the attending
physician, usually after consultation with an infectious
disease specialist or microbiologist. The decision would be
conditional, based on observation of a favourable clinical
Table 1 Description of
different TMP–SMX doses
TMP (mg/kg/day) SMX (mg/kg/day) Standard dose used in the study
High dose 15–20 75–100 Not used
Intermediate dose 10–15 50–75 2400 mg b.i.d.
Low dose 4–6 20–30 960 mg b.i.d.
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response to initial therapy or in case of development of
toxicity.
The intermediate-dose group consisted of patients who
received at least 2 weeks of the intermediate dose of TMP–
SMX. Patients who were switched to low-dose TMP–SMX
during treatment were included in the step-down group.
Data collection and analyses
For all included patients, clinical data about underlying
disease, symptoms and laboratory values at presentation
were extracted from the electronic patient files. Because
the assay used to measure lactate dehydrogenase (LDH)
levels was altered during the study period, we defined an
elevated LDH as more than 1.5 times the upper limit of
normal. Data concerning the diagnostic workup for PCP,
the occurrence of ICU admission, length of hospitalization,
30-day relapse rate of PCP, 30- and 100-day all-cause
mortality and recorded adverse events were documented.
Variables were compared between treatment groups. In
addition, the 30-day mortality data were analysed in a case-
by-case review. The cause of death was classified as either
attributable to PCP (e.g. respiratory failure), contributable to
PCP (e.g. secondary bacterial sepsis) or not related to PCP
(e.g. gastrointestinal bleeding, myocardial infarction).
Statistical analyses were performed with the SPSS ver-
sion 20.0 statistical package for Windows. Univariate risk
factor analysis for binominal variables was performed
using cross tables and Chi square statistical tests. Results
are reported as risk ratios (RR) with 95 % confidence
intervals (CI95 %). For continuous variables, a Student’s
t test or Mann–Whitney U test was performed depending
on the distribution of the respective variable. A p value
of\0.05 was considered to be significant. The observa-
tional study design leads to an inevitable confounding by
indication. The effects of this bias and interpretation of
results are discussed in detail in ‘‘Discussion’’.
Results
Study cohort
Out of 163 potential cases of PCP retrieved by query from
the databases of the departments of medical microbiology
and pharmacy, 132 patients with a confirmed diagnosis of
PCP were identified. Ten patients were treated with a
regimen other than TMP–SMX, eight patients received a
dose of TMP–SMX that could not be classified per protocol
in one of the two defined treatment groups and two patients
were solely treated with low-dose TMP–SMX. One patient
was a child. Seven patients prematurely terminated treat-
ment before the end of 2 weeks. For five patients, this was
due to toxicity and for two patients the reason was
unknown. A total of 104 adult patients were included in the
study cohort (Fig. 1).
Eighty patients (77 %) received the standard treatment of
at least 2 weeks of intermediate-dose TMP–SMX. The
majority of these patients (73 patients, 91 %) were treated
for 2 weeks. Six patients were treated for 3 weeks and one
patient was treated for 4 weeks. Twenty-four patients of the
study cohort (23 %) were included in the step-down group.
They were switched to low-dose TMP–SMX at a median of
4.5 days (IQR 2.8–7.0 days). In the whole study cohort,
only one patient used TMP–SMX prophylaxis (480 mg
o.d.) prior to diagnosis of PCP. This patient was recently
diagnosed with HIV infection and had started taking pro-
phylaxis only 15 days prior to the diagnosis of PCP.
Respiratory material was obtained from all patients as
required by definition for a confirmed diagnosis of PCP.
A BAL was performed in 99 (95 %) of the cases. In the
remaining five patients, two patients in the step-down
group and three patients in the intermediate-dose group,
diagnostic tests were performed on sputum. Microscopy for
P. jirovecii cysts was positive in 14 patients (70 %) in the
step-down group and in 41 patients (57 %) in the inter-
mediate-dose group.
Fig. 1 The study cohort
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Clinical characteristics at presentation
The clinical characteristics at presentation with PCP are
described in Table 2. The LDH serum level was more
frequently elevated in the intermediate-dose group
(p = 0.048). None of the other studied variables discrim-
inated between the two treatment groups.
Mortality and relapse
The 30-day all-cause mortality was 13 % (14 patients).
There was one death in the step-down group (4 %) versus
13 deaths (16 %) in the intermediate-dose group (p = 0.13,
Table 3). The 14 patients with 30-day mortality are shown
in Table 4. The patients died at a median of 14 days (IQR





Risk ratioa (95 %
CI)
p value#
Clinical parameters at admission
Gender M/F ratio 16/8 46/34 1.36 (0.64–2.87) 0.42
Age (years) 61 (47–71) 60 (49–64) 0.43
Age[ 50 years 17 (71) 59 (74) 0.89 (0.46–1.93) 0.78
Age[ 65 years 9 (38) 21 (44) 1.55 (0.77–3.14) 0.23
Duration of respiratory symptoms at diagnosis 7 (3–19) 10 (3–14) 0.87
Temperature (C) 37.8 (37.3–38.8) 37.7 (37.0–38.3) 0.27
Respiratory rate (breaths per min) 24 (20–30) 23 (16–30) 0.33
Underlying condition
HIV infection 5 (21) 12 (15) 1.35 (0.58–3.11) 0.50
Solid organ transplantation 6 (25) 27 (34) 0.72 (0.31–1.64) 0.42
Haematology malignancy 7 (29)b 25 (31) 0.93 (0.43–2.01) 0.85
Other 7 (29) 16 (20) 1.44 (0.68–3.07) 0.34
Laboratory results
Leukocyte count (9109/l) 7.2 (3.6–10.9) 7.2 (4.8–11.3) 0.91
Leukocyte count elevated ([ULN) 8 (33) 26 (33) 1.00 (0.48–2.13) 0.97
C-reactive protein (mg/l) 74 (36–153) 92 (48–194) 0.43
C-reactive protein[100 mg/l 10/21 (48) 28/61 (46) 1.05 (0.50–2.20) 0.89
Creatinine (lmol/l) 86 (74–134) 88 (64–147) 0.52
Creatinine elevated ([1.5 ULN) 5 (21) 20 (25) 0.82 (0.34–1.97) 0.65
Lactate dehydrogenase elevated ([1.5 ULN) 7/23 (30) 42/78 (54) 0.46 (0.21–1.03) 0.048
PaO2 (kPa) 7.9 (6.5–9.2) 7.9 (6.9–8.8) 0.84
Indication for steroid treatment [PaO2
(kPa)\ 9.0]
11/16 (69) 48/61 (79) 0.67 (0.27–1.68) 0.40
Start steroid schedule at diagnosis 21/23 (91) 55/65 (85) 1.67 (0.44–6.17) 0.42
Outcome of diagnostic methods on BAL
PCR positive 24 (100)c 76 (100)d – –
Microscopy positive 14/20 (70) 41/72 (57) 1.49 (0.66–3.72) 0.29
Ct value 33.7 (30.4–34.6) 34.1 (30.7–37.1) 0.74
Values represent median (IQR Q1–Q3) or no. (%)
PCP Pneumocystis jirovecii pneumonia, CI confidence interval, HIV human immunodeficiency virus, ULN upper limit of normal, BAL bron-
choalveolar lavage, PCR polymerase chain reaction, IQR interquartile range
# p value as calculated by Pearson Chi square test for bivariate variables and by Mann–Whitney U test or independent samples Student’s t test
(according to distribution) for continuous variables
a Risk ratios are for risk of switch to low-dose treatment
b One patient in the step-down group with both non-Hodgkin lymphoma and a kidney transplantation
c In two cases, there was only a positive sputum PCR and no BAL performed
d In three cases, there was only a positive sputum PCR and no BAL performed; in four cases PCR was not performed, but microscopy was
positive
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9–18) after diagnosis of PCP. In two patients (14 %), the
mortality was not related to PCP (1 patient with multi-
organ failure and upper gastrointestinal bleeding and 1
patient with hypovolemic shock due to abdominal bleed-
ing). In three patients (21 %), PCP contributed to mortality
and in eight patients (57 %) death was attributable to PCP.
One patient died of unknown cause. In the only patient who
died in the step-down group, death was attributable to PCP.
The 100-day mortality was 8 % (2 patients) and 25 %
(20 patients) for the step-down and intermediate-dose
groups, respectively (p = 0.08).
There was one relapse in the low-dose group occurring
19 days after the initial episode. In this patient, the dif-
ferential diagnosis was immune reconstitution inflamma-
tory syndrome (IRIS) 10 days after starting combination
antiretroviral therapy (cART) for a newly diagnosed HIV
and PCP. In the second episode he recovered with steroid
treatment only, although P. jirovecii was again detected in
a fluid specimen from a second BAL.
Of note, the median length of hospitalization was
14.5 days in the step-down group versus 15 days in the
intermediate-dose group (p = 0.91). ICU admission tended
to be less frequent in the step-down group (17 vs. 33 %,
p = 0.13). In a multivariate analysis adjusted for age and
co-morbidity, CRP levels and the partial oxygen pressure at
presentation were variables independently associated with
later admission to the ICU (data not shown).
Toxicity
Toxicity was more frequently reported in the step-down
group, five patients in the step-down group (21 %) versus
four patients in the intermediate-dose group (5 %). The
reported toxicity included rash (5 patients), hepatotoxicity
(2 patients), hyperkalaemia (2 patients) and renal insuffi-
ciency (1 patient). Toxicity was the reason to switch to
low-dose TMP–SMX for the five patients in the step-down
group after a median of 7 days of treatment. These five
patients (4 with rash, 1 with elevated liver enzymes) con-
tinued their low-dose treatment with satisfactory results.
Discussion
TMP–SMX doses and treatment outcome of PCP
The results suggest that treatment of PCP with an inter-
mediate dose of TMP–SMX has comparable efficacy as the
recommended high-dose regimen. In addition, a step-down
to low-dose TMP–SMX is likely an option for patients with
a favourable clinical course and/or patients who already
developed TMP–SMX-related toxicity. There was no
increase in treatment failure or relapse in the step-down
group.
Our experience with the intermediate dose of TMP–
SMX complies with two previous studies in which a sim-
ilar intermediate-dose regimen was used [11, 12]. Thomas
et al. conducted a retrospective review of 73 HIV-infected
patients with PCP treated with TMP 10 mg/kg/day and
SMX 50 mg/kg/day. The relapse rate was 7 %. A low
mortality rate of 7 % was reported, though ICU admission
was only indicated in 12 % of cases. Bowden et al. con-
ducted a randomized trial of 30 HIV-infected patients who
received either TMP 20 mg/kg/day–SMX 100 mg/kg/day





Risk ratioa (95 %
CI)
p value#
ICU admission and hospital stay
ICU admission 4 (17) 26 (33) 0.49 (0.18–1.32) 0.13
Length of hospitalization (days) 15 (9–24) 15 (8–33) 0.91
Toxicity
(Pre-switch) in file reported TMP–SMX
toxicity
5 (21) 4 (5) 2.78 (1.37–5.65) 0.02
Outcome
30-day relapse rate 1 (4) 0 – 0.06
30-day mortality 1 (4) 13 (16) 0.28 (0.04–1.91) 0.13
100-day mortality 2 (8) 20 (25) 0.34 (0.09–1.33) 0.08
Values are median (IQR Q1–Q3) or no. (%)
PCP Pneumocystis jirovecii pneumonia, CI confidence interval, ICU intensive care unit, IQR interquartile range
# p value as calculated by Pearson Chi square test for bivariate variables and by Mann–Whitney U test or independent samples Student’s t test
(according to distribution) for continuous variables
a Risk ratios are for risk of switch to low-dose treatment
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or TMP 10 mg/kg/day–SMX 50 mg/kg/day, with no dif-
ferences in treatment failures. Mortality was not reported,
but only patients with mild PCP were included. To the best
of our knowledge, there is only one previous study that
investigated a step-down regimen of TMP–SMX for the
treatment of PCP [13]. Eeftinck Schattenkerk et al. retro-
spectively reviewed the case records of 50 patients with
AIDS and PCP in the era prior to both cART and additional
steroid therapy in the treatment of PCP. When drug intol-
erance developed, patients were switched to maintenance
dose TMP–SMX (TMP 160 mg and SMX 800 mg o.d.). In
this study, 20 patients were switched to maintenance-level
TMP–SMX after an average of 9.6 days. There was no
relapse in this group and overall survival was comparable
with the group that received 2 weeks of high-dose TMP–
SMX.
In contrast to this approach, the current protocol allowed
patients with improving condition to switch also if no
adverse events due to TMP–SMX were observed. Never-
theless, more adverse events were reported in the step-down
group than in the intermediate-dose group, suggesting that
the appearance of toxicity was an important incentive for
physicians to pursue a switch to low-dose TMP–SMX.
After the appearance of TMP–SMX toxicity, five patients
were able to complete their treatment with low-dose TMP–
SMX, thereby avoiding the use of alternative regimens like
pentamidine or clindamycin plus primaquine.
Our study cohort contains many severe cases of PCP, i.e.
ICU admission was required in 29 % of cases. The overall
30-day mortality rate of 13 % in our study is comparable to
or even lower than the mortality rates of 12–18 %, reported
from earlier studies. In these studies, a high dose of TMP–
SMX was used for HIV-related PCP, with concomitant
additional steroid treatment if indicated [7, 15–18]. Mor-
tality rates for PCP in immunocompromised HIV-negative
patients have been found to be even higher (35–50 %) [19–
21].
Clinical parameters and step-down to low-dose
TMP–SMX
The current study did not identify the clinical characteris-
tics at the time of diagnosis that were predictive of a suc-
cessful switch to low-dose TMP–SMX. Lower levels of
LDH were present in the step-down group, but this
parameter was not sufficiently discriminative. Notably,
clinical variables known to be predictive for an unfavour-
able outcome, e.g. age, partial oxygen pressure and high
C-reactive protein (CRP) [22–24], were not different
between the two treatment groups. In a separate analysis
(data not shown), the correlation between mortality and
high CRP as well as low partial oxygen pressure at pre-
sentation was confirmed in our cohort. Several factors may
explain the fact that the clinical characteristics—at pre-
sentation—usually associated with a favourable outcome
were not found to be associated with a switch to low-dose
treatment. First, a subcategory of patients that continued
treatment on intermediate-dose TMP–SMX might have
done well also after switch to low-dose therapy. The
opportunity to switch may simply have been missed by the
attending physicians. Secondly, the decision to switch to
low-dose therapy was made during the course of treatment
and not at presentation. Reassessment of clinical variables
at the time of consideration of decreasing the dose of
TMP–SMX could more accurately disclose which clinical
variables predict a successful step-down strategy.
Pharmacology of TMP–SMX and treatment of PCP
Because of the difficulties of propagating P. jirovecii for a
prolonged time in vitro, minimal inhibitory concentrations
(MICs) and clinical breakpoints have not been obtained for
TMP–SMX with regard to treatment of PCP [25–27]. Data
from animal studies on this subject are available but concern
different Pneumocystis species, e.g. P. carinii [4]. The
results of these investigations may not be easily extrapolated
to PCP in humans. TMP–SMX has excellent bioavailability,
nearly 100 % after oral administration [28]. For trimetho-
prim, serum levels of 2 lg/ml are reached after ingestion of
960 mg of TMP–SMX, and remain stable for approximately
6 h, after which the concentration steadily falls [29]. The
TMP to SMX concentration ratio in cotrimoxazole is 1:5,
but in serum it reaches a concentration ratio of 1:20 and both
compounds are bound to serum proteins for approximately
two-thirds of their total concentration [30]. As a conse-
quence, a dose of 960 mg cotrimoxazole b.i.d. would
approximately result in effective (i.e. unbound) concentra-
tions of 0.67 and 13.3 lg/ml of TMP and SMX, respec-
tively, for 12 per 24 h. From in vitro studies, the estimates of
the IC90 of SMX for P. carinii (i.e. rat Pneumocystis) were
found to be 8 lg/ml (trophozoites) and 16 lg/ml (cysts)
when combined with 0.5 lg/ml TMP [31]. Although results
of such experiments have not been published for P. jirovecii,
this suggests that effective killing of P. jirovecii for over
50 % of the time treated with cotrimoxazole 960 mg b.i.d. is
expected. However, further in vitro study of P. jirovecii
susceptibility is needed to provide a stronger pharmacolog-
ical basis for the rationale of treatment with low-dose TMP–
SMX. Due to good tissue penetration, concentrations of
TMP and SMX in organs have frequently been found to be
higher than serum concentrations [32, 33].
Study limitations and strengths
Because of its non-randomized design, equal effectiveness
or non-inferiority of the executed strategy cannot be
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claimed. The obvious confounding by indication also
explains the higher mortality in the intermediate-dose
group, and patients with a favourable clinical course would
be more prevalent in the step-down group. In addition,
toxicity was an important reason for the attending physi-
cian to switch to low-dose TMP–SMX, accounting for the
high frequency of reported toxicity in the step-down group.
The study included a substantial number of patients and
the clinical practice setting is representative of standard
diagnostic workup and care for patients with PCP. Differ-
ent groups of immunocompromised patients are equally
represented in both groups. This emphasizes that the step-
down approach was followed regardless of the underlying
immunodeficiency of the patient. Therefore, differences
between PCP in HIV and non-HIV infected patients
probably do not impair the interpretation of the results [34,
35].
Conclusions
Despite the observational design of the study, the results
strongly suggest that treatment of PCP with intermediate-
dose TMP–SMX has a similar efficacy compared to treat-
ment with the recommended high-dose regimen. A ran-
domized controlled trial would be necessary to provide
clear evidence that both regimens are equally effective.
Since the superiority of the high-dose regimen over an
intermediate-dose or even over a low-dose regimen was
never established by modern epidemiological standards in
any clinical trial, the standard use of an intermediate-dose
TMP–SMX as PCP therapy is—at the very least—open for
discussion. The issue of lower frequency of severe toxic
side effects, i.e. neutropenia, drug-induced hepatitis and
rash, observed in patients who use an intermediate dose
herein plays an important role.
In addition, a consecutive step-down strategy to low-
dose TMP–SMX appears to be successful in selected
patients, regardless of underlying disease and clinical
characteristics at presentation. In case of development of
toxicity during treatment with intermediate-dose TMP–
SMX, our results confirm that most of these patients are
able to complete treatment with low-dose TMP–SMX.
Further studies should focus on optimizing the balance
between efficacy and toxicity of TMP–SMX by patient-
tailored treatment of PCP.
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